NCT06440083

Brief Summary

The goal of this observational study is to identify potential indicators for pre-warning of sudden cardiac death (SCD), including clinical biochemistry markers, electrocardiogram, echocardiography, MRI and CT imaging values, genetic markers and so on, and further construct a series of multi-parameter assessments of SCD early screening.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100,000

participants targeted

Target at P75+ for all trials

Timeline
19mo left

Started Mar 2023

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress68%
Mar 2023Dec 2027

Study Start

First participant enrolled

March 2, 2023

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

May 28, 2024

Completed
6 days until next milestone

First Posted

Study publicly available on registry

June 3, 2024

Completed
3.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2027

Last Updated

June 5, 2024

Status Verified

June 1, 2024

Enrollment Period

4.8 years

First QC Date

May 28, 2024

Last Update Submit

June 3, 2024

Conditions

Keywords

Sudden Cardiac DeathCohort study

Outcome Measures

Primary Outcomes (1)

  • Sudden cardiac death

    Identify participants who die by cardiovascular diseases during follow-up period

    Baseline and to the 1-year, 2-year, 5-year follow-up

Secondary Outcomes (4)

  • All-causes death

    Baseline and to the 1-year, 2-year, 5-year follow-up

  • Recurrence of cardiovascular disease

    Baseline and to the 1-year, 2-year, 5-year follow-up

  • Cardiac arrest

    Baseline and to the 1-year, 2-year, 5-year follow-up

  • Major cardiovascular events

    Baseline and to the 1-year, 2-year, 5-year follow-up

Eligibility Criteria

Age16 Years - 90 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Participants with potential high-risk of sudden cardiac death.

You may qualify if:

  • The subjects with the following diagnosis of one or more cardiovascular diseases:
  • Coronary heart disease If there is a history of coronary heart disease or a new diagnosis of coronary heart disease, or with a report of coronary angiography that indicates at least one vascular stenosis\>50%. Diagnosis includes chronic coronary syndrome (stable angina, ischemic cardiomyopathy, and occult coronary heart disease) and acute coronary syndrome (unstable angina, ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction).
  • Heart failure Individuals with a history of heart failure or newly diagnosed heart failure, including heart failure with reduced ejection fraction (HFrEF, left ventricular ejection fraction (LVEF) ≤40%)、intermediate heart failure (HFmrEF, LVEF 41%-49%,with evidence of spontaneous or excitable increase in left ventricular filling pressure), and ejection fraction preserving heart failure (HFpEF, LVEF≥50%, there is evidence of spontaneous or excitable increase in left ventricular filling pressure).
  • Genetically related cardiomyopathy or arrhythmia Cardiomyopathy includes hypertrophic cardiomyopathy (DCM), dilated cardiomyopathy (HCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), inflammatory cardiomyopathy (myocarditis, sarcoidosis, Chagas disease). Hereditary arrhythmias include long QT syndrome, short QT syndrome, Brugada syndrome, idiopathic ventricular fibrillation, catecholamine sensitive polymorphic ventricular tachycardia (CPVT), early repolarization syndrome, etc.
  • \) Sign an informed consent form.

You may not qualify if:

  • Age\<16 years old;
  • Refusal to the follow-up visits;
  • Individuals with severe mental disorders who are unable to express their wishes;
  • Other obvious physical diseases and abnormal laboratory test results;
  • Patients deemed unsuitable for participation in this study by the supervising physician.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sun Yat-sen Memorial Hospital of Sun Yat-sen University

Guanzhou, Guangdong, 510120, China

RECRUITING

MeSH Terms

Conditions

Death, Sudden, Cardiac

Condition Hierarchy (Ancestors)

Heart ArrestHeart DiseasesCardiovascular DiseasesDeath, SuddenDeathPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Jingfeng Wang, M.D.,Ph.D.

    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Yuling Zhang, M.D.,Ph.D.

CONTACT

Maohuan Lin, M.D.,Ph.D.

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

May 28, 2024

First Posted

June 3, 2024

Study Start

March 2, 2023

Primary Completion (Estimated)

December 31, 2027

Study Completion (Estimated)

December 31, 2027

Last Updated

June 5, 2024

Record last verified: 2024-06

Locations